CMND Clearmind Medicine Inc. IFRS
Pharmaceutical Preparations · Nasdaq · SEC CIK 1892500 · Fiscal year ends 10/31
Financial factors as of 2026-01-31 (2026Q1), TTM = sum of the last four quarters
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q1*2026-01-31 | 2025Q4*2025-10-31 | 2025Q3*2025-07-31 | 2025Q2*2025-04-30 | 2025Q1*2025-01-31 | 2024Q4*2024-10-31 | 2024Q3*2024-07-31 | 2024Q2*2024-04-30 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $640,494 | $420,182 | $723,048 | $451,857 | $461,438 | $486,491 | $345,883 | $322,956 |
| SG&A expense | $3.02M | $1.04M | $684,716 | $855,124 | $1.03M | $1.10M | $1.13M | $980,549 |
| Pretax income | -$3.85M | -$685,648 | -$1.31M | -$763,270 | -$1.03M | -$787,624 | -$2.05M | -$871,461 |
| Income tax | $3,960 | $2,194 | $8,258 | $20,658 | $39,335 | $97,120 | $42,590 | $36,756 |
| Net income | -$3.85M | -$687,842 | -$1.31M | -$783,928 | -$1.07M | -$884,744 | -$2.09M | -$908,217 |
| EPS (basic) | -3.32 | — | -0.25 | -0.16 | -9.55 | — | -0.59 | -0.28 |
| EPS (diluted) | -3.32 | — | -0.25 | -0.16 | -9.55 | — | -0.59 | -0.28 |
| Weighted avg. shares (diluted) | 1.16M | — | 5.34M | 5.04M | 112,213 | — | 3.56M | 3.25M |
| Balance sheet | ||||||||
| Cash & equivalents | $9.26M | $3.92M | $3.50M | $4.47M | $5.78M | $6.57M | $7.68M | $8.31M |
| Short-term investments | $1.09M | $1.66M | $1,084 | $177,640 | $134,723 | $289,388 | — | — |
| Current assets | $11.02M | $5.95M | $3.82M | $5.02M | $6.41M | $7.09M | $7.99M | $8.69M |
| PP&E, netmay include right-of-use assets (IFRS) | — | — | — | — | — | — | $355 | $624 |
| Intangibles | $94,611 | $97,372 | $100,133 | $102,894 | $105,565 | $108,326 | $111,087 | $113,848 |
| Total assets | $11.14M | $6.08M | $3.97M | $5.18M | $6.58M | $7.26M | $8.17M | $8.85M |
| Current liabilities | $2.91M | $4.89M | $2.90M | $2.88M | $3.72M | $4.13M | — | $4.20M |
| Total liabilities | $2.91M | $4.89M | $2.90M | $2.88M | $3.73M | $4.15M | $4.70M | $4.20M |
| Shareholders' equity | $8.24M | $1.19M | $1.07M | $2.30M | $2.85M | $3.11M | $3.47M | $4.65M |
| Cash flow statement | ||||||||
| Operating cash flow | -$2.08M | -$1.29M | -$1.08M | -$1.10M | -$1.27M | -$1.08M | -$1.13M | -$1.19M |
| Investing cash flow | — | -$524,433 | $112,954 | -$200,000 | $69,462 | -$350,400 | $33,803 | — |
| Financing cash flow | $7.42M | $2.24M | -$10,812 | -$10,298 | $404,812 | $323,205 | $469,537 | $145,129 |
| Stock-based compensation | $1.41M | $115,640 | $77,790 | $231,722 | $380,738 | $182,498 | $377,279 | $290,091 |
Free plan shows the latest 8 periods; Pro shows all 15 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.